What’s the next big thing coming for healthcare?

Results from the New England Journal of Medicine (NEJM) Catalyst Insights Survey on Care Redesign suggest that genomics and patient-generated data critical for precision medicine could surge in importance over the next five years. Savvy investors could profit from this increased demand for precision medicine data by buying two specific stocks: Illumina (NASDAQ: ILMN) and Roche(NASDAQOTH: RHHBY). Here’s why.